Today’s the day! The H-SPAN Summit D.C. agenda is officially LIVE!
Check out our incredible lineup of sessions and speakers here: https://t.co/UMOAcjMzUH
Let us know who you’re most excited to see by commenting below!
For the next week, get 20% off a ticket using promo code: HEALTHSPAN
On June 8th, A4LI and a strong representation of academic and biotechnology leaders in longevity will join CA Senator Josh Becker (@SenJoshBecker) as he presents Senate Resolution 104.
SR 104 advocates for a fundamental shift in how California approaches public health and fiscal planning regarding the state's aging population. The resolution encourages state health and aging departments to integrate geroscience into public health programming while fostering collaboration among academia, health plans, and biotechnology firms to pilot innovative longevity medicines and gerotherapeutics.
This is an incredible milestone for California, the leading state for investment, talent, and innovation in the longevity science field!
Resolution Text: https://t.co/4C4H2MxY2z
#CA #Healthspan #LongevityScience #A4LI
The H-SPAN Summit D.C. is only ONE MONTH away!
Join us as we bring together researchers, policymakers, innovators, and advocates working to accelerate progress against age-related diseases and advance the future of medicine.
Registration and Agenda Here: https://t.co/UMOAcjM259
Hosting our Summit at Georgetown University’s Capitol Campus allows us to do so much more! We will have quick pitches, workshops, and a poster session for everyone to participate in!
Check out the full schedule and get your ticket today: https://t.co/va0pAei2y6
I’m thrilled to announce my new podcast, Longevity Science with Matt Kaeberlein.
Episode 1 is now live and takes a deep dive into the story of dinitrophenol (DNP) — an experimental weight loss drug linked to hundreds of deaths and a cautionary reminder of what can happen when enthusiasm for new therapies gets ahead of the science.
Episode 2 drops Friday and features a Longevity Roundtable with @BKennedy_aging and @docmranney . We discuss proactive healthcare, rapamycin, peptides, epigenetic reprogramming, biological age testing, and where the field of longevity medicine may be headed next.
My goal with this channel is simple: thoughtful, evidence-based conversations that separate signal from noise in the rapidly evolving world of longevity science.
I hope you’ll check it out — and subscribe on YouTube, Spotify, or wherever you listen to podcasts.
YouTube: https://t.co/gMJLYOf5aj
Spotify: https://t.co/q12wY567gA
The passage of HB 1734 and HB 1735 is a no-brainer, and it is disappointing how much pushback it is receiving from the “pro-business,” “pro-freedom” and “pro-life” Republicans on the Senate Health and Human Services Committee. There are countless lives that can be helped — from early stage chronic disease to rare disease patients, all of whom have no other options. If you live in NH, call your Senators and demand these bills get passed. If you know someone in NH, do the same.
@KellyAyotte — thank you for your support, your leadership, and your ability to see things clearly and with reason.
@roche4nh — you are making lives worse and actively hurting your state. As a pharmacist, you of all people should understand what’s at stake for patients who have run out of options. You still have a chance to get this right. Do the right thing.
The Alliance for Longevity Initiatives (A4LI) would like to provide an update regarding New Hampshire’s ongoing efforts to expand patient access to investigational medical treatments and strengthen the state’s position as a hub for biomedical innovation.
This week, legislative language from HB1734 and HB1735 was successfully attached to SB504 through the amendment process in the New Hampshire House of Representatives, keeping these reforms active as negotiations continue.
HB1734 would authorize the establishment of experimental treatment centers capable of offering eligible investigational therapies under state oversight, while HB1735 would expand New Hampshire’s Right to Try framework to include patients suffering from chronic and debilitating conditions
We would especially like to thank House Speaker Sherman Packard (@NHSpeaker) and Majority Leader Jason Osborne (@Osborne4NH) for their leadership and continued support. Together, these proposals continue New Hampshire’s emergence as one of the most forward-looking states in the country on medical innovation, patient autonomy, and access to next-generation therapies.
As the process continues, we encourage everyone to respectfully reach out to Senate President Sharon Carson, Senator Rochefort, and Senator Birdsell and urge them to support SB504 as amended during committee of conference negotiations.
We look forward to continuing to work with lawmakers, patients, advocates, and innovators as this effort progresses.
𝐖𝐞 𝐚𝐫𝐞 𝐥𝐢𝐯𝐢𝐧𝐠 𝐥𝐨𝐧𝐠𝐞𝐫, 𝐛𝐮𝐭 𝐰𝐞 𝐚𝐫𝐞𝐧'𝐭 𝐥𝐢𝐯𝐢𝐧𝐠 𝐡𝐞𝐚𝐥𝐭𝐡𝐢𝐞𝐫.
Sixty percent of the global disease burden is now tied to chronic, age-related conditions. We are trading quick deaths for decades of disability, and it’s time for the NIH to fund the solution, not just manage the decline.
As the NIH requests input for its Strategic Plan for FY 2027-2031, the Alliance for Longevity Initiatives is proposing a Disease-Burden Framework. Our proposal recommends that research funding be allocated by actual disease burden, measured by DALYs (Disability-Adjusted Life Years) from the Global Burden of Disease Study.
This isn't a new concept—a framework like this already exists with the Onco-Aging Consortium within the NCI and NIA. Now, it’s time to expand this successful model across all major disease institutes—NHLBI, NIDDK, NEI, NINDS, and NIDCD.
𝐖𝐡𝐢𝐜𝐡 𝐢𝐧𝐬𝐭𝐢𝐭𝐮𝐭𝐞 𝐝𝐨 𝐲𝐨𝐮 𝐭𝐡𝐢𝐧𝐤 𝐰𝐨𝐮𝐥𝐝 𝐛𝐞𝐧𝐞𝐟𝐢𝐭 𝐦𝐨𝐬𝐭 𝐟𝐫𝐨𝐦 𝐚 𝐟𝐨𝐫𝐦𝐚𝐥 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐍𝐈𝐀? 𝐋𝐞𝐭'𝐬 𝐝𝐢𝐬𝐜𝐮𝐬𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐞𝐧𝐭𝐬.
𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐩𝐫𝐨𝐩𝐨𝐬𝐚𝐥 𝐚𝐧𝐝 𝐬𝐢𝐠𝐧 𝐨𝐧 𝐲𝐨𝐮𝐫 𝐬𝐮𝐩𝐩𝐨𝐫𝐭: 🔗https://t.co/oRxWXrME2X
@theA4LI Institutes like the NEI and NIDCD play an understated yet critical role in longevity. These institutes protect the sensory inputs that define our quality of life and we often take them for granted, so I'm excited and very supportive of these consortia with the NIA!
This paper exists because teams of people started an unglamorous data collection project many years ago.
The Interventions Testing Program (ITP) is a long-running project by the NIH-NIA with the goal to identify interventions that extend lifespan in mice. The ITP was not built around the analysis this paper eventually performed. Instead, the paper’s method emerged because a group of scientists had access to a sufficiently large dataset generated by the ITP and realized there were better questions to ask of it.
Computational power is scaling rapidly. What isn't scaling is the generation of biological data that requires organisms to age, populations to evolve, or longitudinal measurements to accumulate across years.
If someone starts a 10-year dataset now, by the time it matures the analytical tools available to interrogate it will be dramatically more powerful than anything we have today.
But if nobody starts the dataset, those tools have nothing to work with.
For those thinking about the overall progress of longevity, it’s now obvious that AI will be bottlenecked by the lack of high quality biological datasets.
https://t.co/mEXSgsAH3t
While the festival season is heating up, we’re preparing for a different kind of "performance" in Washington, D.C. We are thrilled to be one of the most exciting lineups this summer, bringing together the leading voices in longevity and policy for the 3rd Annual H-SPAN Summit. 😎
Check back next week for the full detailed agenda here: https://t.co/UMOAcjMzUH